The influence of site of metastasis on tumour growth and response to chemotherapy. (original) (raw)

Br J Cancer. 1975 Jul; 32(1): 78–86.

This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.

Abstract

Drug screening trials and general treatment of solid tumours in advanced cancer patients have been concerned only with the site of primary origin, regardless of where metastases might have seeded. Since the environment for tumour growth can differ appreciably at various anatomical sites, an investigation was undertaken to determine the effect of metastatic site on response to chemotherapy. Data from 1961 to 1965 of the screening trials of the Eastern Clinical Drug Evaluation Program were utilized. Response and location data extensive enough for analysis represented 6 sites of primary origin and 6 metastatic site groups, totalling 1687 lesions. Analysis of percentage reduction in tumour size after chemotherapy regimens of up to 60 days revealed a significant amount of variation associated with metastatic sites and a non-significant amount associated with sites of primary origin. Advanced primary tumours showed marked variation in responsiveness and some showed a difference in response to different drug groups. Generally, metastases responded better than the advanced primaries from which they were derived, except for those from breast tumours.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (1.1M), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

Breur K. Growth rate and radiosensitivity of human tumours. I. Growth rate of human tumours. Eur J Cancer. 1966 Jun;2(2):157–171. [PubMed] [Google Scholar]
Moore GE, Bross ID, Ausmans R, Nadler S, Jones R, Jr, Slack N, Rimm AA. Effects of 5-fluorouracil (NSC-19893) in 389 patients with cancer. Eastern Clinical Drug Evaluation Program. Cancer Chemother Rep. 1968 Oct;52(6):641–653. [PubMed] [Google Scholar]
Rambert P, Malaise E, Laugier A, Schilienger M, Tubiana M. Données sur la vitesse de croissance de tumeurs humaines. Bull Cancer. 1968 Jul-Sep;55(3):323–341. [PubMed] [Google Scholar]
SCHNEIDERMAN MA. The clinical excursion into 5-fluo-rouracil. Cancer Chemother Rep. 1962 Feb;16:107–118. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK